1.
Stern EP, Denton CP. The pathogenesis of systemic sclerosis. RheumDis Clin. 2015;41(3):367-382. doi: 10.1016/j.rdc.2015.04.002
2.
Pagkopoulou E, Arvanitaki A, Daoussis D, Garyfallos A, Kitas G,Dimitroulas T. Comorbidity burden in systemic sclerosis: beyonddisease-specific complications. Rheumatol Int. 2019;39(9):1507-1517. doi: 10.1007/s00296-019-04371-z
3.
Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends inmortality in patients with systemic sclerosis over 40 years: asystematic review and meta-analysis of cohort studies. Rheumatol.2011;51:1017-1026. doi: 10.1093/rheumatology/ker269
4.
Domsic R, Fasanella K, Bielefeldt K. Gastrointestinalmanifestations of systemic sclerosis. Dig Dis Sci. 2008;53(5):1163-1174. doi: 10.1007/s10620-007-0018-8
5.
Thoua NM, Bunce C, Brough G, Forbes A, Emmanuel AV, DentonCP. Assessment of gastrointestinal symptoms in patients withsystemic sclerosis in a UK tertiary referral centre. Rheumatol.2010;49(9):1770-1775. doi: 10.1093/rheumatology/keq147
6.
Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors fordeath in systemic sclerosis: a study from the EULAR SclerodermaTrials and Research (EUSTAR) database. Ann Rheum Dis.2010;69(10):1809-1815. doi: 10.1136/ard.2009.114264
7.
Frantz C, Avouac J, Distler O, et al. Impaired quality of life insystemic sclerosis and patient perception of the disease: a largeinternational survey. Semin Arthritis Rheum. 2016;46(1):115-123. doi: 10.1016/j.semarthrit.2016.02.005
8.
Steen VD, Medsger Jr TA. Severe organ involvement insystemic sclerosis with diffuse scleroderma. Arthritis Rheum.2000;43(11):2437-2444. doi: 10.1002/1529-0131(200011)43:11<2437::Aid-anr10>3.0.Co;2-u
9.
Richard N, Hudson M, Wang M, et al. Severe gastrointestinaldisease in very early systemic sclerosis is associated withearly mortality. Rheumatol. 2019;58(4):636-644. doi: 10.1093/rheumatology/key350
10.
Baron M, Bernier P, Côté LF, et al. Screening and therapy formalnutrition and related gastro-intestinal disorders in systemicsclerosis: recommendations of a North American expert panel.Clin Exp Rheumatol. 2010;28(Suppl 58):S42-S46.
11.
van den Hoogen F, Khanna D, Fransen J, et al. 2013classification criteria for systemic sclerosis: an Americancollege of rheumatology/European league against rheumatismcollaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755.doi: 10.1136/annrheumdis-2013-204424
12.
Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessmentof organ manifestations in systemic sclerosis: a report from theEULAR Scleroderma Trials And Research group database. AnnRheum Dis. 2007;66(6):754-763. doi: 10.1136/ard.2006.062901
13.
Smirani R, Poursac N, Naveau A, Schaeverbeke T, Devillard R,Truchetet ME. Orofacial consequences of systemic sclerosis: asystematic review. J Scleroderma Relat Disord. 2018;3(1):81-90.doi: 10.1177/2397198317746966
14.
Khanna D, Hays RD, Maranian P, et al. Reliability and validity ofthe University of California, Los Angeles Scleroderma ClinicalTrial Consortium Gastrointestinal Tract Instrument. ArthritisCare Res. 2009;61(9):1257-1263. doi: 10.1002/art.24730
15.
Taş YM, Derviş Hakim G, Keskinoğlu P, et al. The validity andreliability study of the University of California, Los AngelesScleroderma Clinical Trial Consortium Gastrointestinal Tract(UCLA SCTC GIT) 2.0 questionnaire for the Turkish society. TurkJ Gastroenterol. 2019;30(3):234-241. doi: 10.5152/tjg.2018.17856
16.
Pope J. (2011) Measures of systemic sclerosis (scleroderma):Health Assessment Questionnaire (HAQ) and SclerodermaHAQ (SHAQ), physician- and patient-rated global assessments,Symptom Burden Index (SBI), University of California,Los Angeles, Scleroderma Clinical Trials ConsortiumGastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline DyspneaIndex (BDI) and Transition Dyspnea Index (TDI) (Mahler’sIndex), Cambridge Pulmonary Hypertension Outcome Review(CAMPHOR), and Raynaud’s Condition Score (RCS). ArthritisCare Res. 2011;63(Suppl 11):S98-S111. doi: 10.1002/acr.20598
17.
Elia M. Screening for malnutrition: a multidisciplinaryresponsibility. Development and use of the MalnutritionUniversal Screening Tool (‘MUST’) for adults. Redditch: BAPEN.2003.
18.
Shreiner AB, Murray C, Denton C, Khanna D. Gastrointestinalmanifestations of systemic sclerosis. J Scleroderma Relat Disord.2016;1(3):247-256. doi: 10.5301/jsrd.5000214
19.
Sakkas LI, Simopoulou T, Daoussis D, Liossis SN, PotamianosS. Intestinal involvement in systemic sclerosis: a clinical review.Digest Dis Sci. 2018;63(4):834-844.
20.
Meier FM, Frommer KW, Dinser R, et al. Update on the profile ofthe EUSTAR cohort: an analysis of the EULAR Scleroderma Trialsand Research group database. Ann Rheum Dis. 2012;71(8):1355-1360. doi: 10.1136/annrheumdis-2011-200742
21.
Nassar M, Ghernautan V, Nso N, et al. Gastrointestinalinvolvement in systemic sclerosis: an updated review. Medicine.2022;101(45):e31780. doi: 10.1097/md.0000000000031780
22.
Baron M, Hudson M, Steele R. Malnutrition is common insystemic sclerosis: results from the Canadian sclerodermaresearch group database. J Rheumatol. 2009;36(12):2737-2743.doi: 10.3899/jrheum.090694
23.
Murtaugh MA, Frech TM. Nutritional status and gastrointestinalsymptoms in systemic sclerosis patients. Clin Nutr.2013;32(1):130-135. doi: 10.1016/j.clnu.2012.06.005
24.
Caimmi C, Caramaschi P, Venturini A, et al. Malnutrition andsarcopenia in a large cohort of patients with systemic sclerosis.Clin Rheumatol. 2018;37(4):987-997. doi: 10.1007/s10067-017-3932-y
25.
Türk İ, Cüzdan N, Çiftçi V, Arslan D, Doğan MC, Unal İ.Malnutrition, associated clinical factors, and depression insystemic sclerosis: a cross-sectional study. Clin Rheumatol.2020;39(1):57-67. doi: 10.1007/s10067-019-04598-y
26.
Caporali R, Caccialanza R, Bonino C, et al. Disease-relatedmalnutrition in outpatients with systemic sclerosis. Clin Nutr.2012;31(5):666-671. doi: 10.1016/j.clnu.2012.02.010
27.
Krause L, Becker MO, Brueckner CS, et al. Nutritionalstatus as marker for disease activity and severity predictingmortality in patients with systemic sclerosis. Ann Rheum Dis.2010;69(11):1951-1957. doi: 10.1136/ard.2009.123273